ClinicalTrials.gg
RecruitingNCT07488754Updated Apr 6, 2026

Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) In Newly Diagnosed Glioma (WHO G3-G4)

An interventional study of Radiation: Local, targeted therapy with alpha emitter [225Ac]Ac-DOTA-SP (TAT) in Glioblastoma, High-Grade Glioma (WHO III-IV) and Glioblastoma (GBM), sponsored by Medical University of Warsaw. Recruiting at 2 sites in Poland. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by Medical University of Warsaw · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Oct 2025, registered Mar 2026).
  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Glioblastoma with a site in Poland — 8 open to participants now, 10 under way, 1 of them phase 3. Glioblastoma · Poland.

Planned enrollment
16th of 20
35 · median 96
Started
2025
with 3 others
No phase
8 of 21
6 open now
Registered
20th of 21
by date
Lead sponsor
5 of 21
Medical University of Warsaw

Among the 21 studies in Glioblastoma with a site in Poland, this one is the 16th largest by planned enrollment of the 20 interventional ones that give a count, is one of 4 that started in 2025, is one of 8 with no phase, and was the 20th registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

8 of the 21 studies in Glioblastoma with a site in Poland are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Glioblastoma with a site in Poland, or all of them as a file.
02

Study summary

Brain tumors account for 1.35% of all cancers and cause 2.2% of cancer-related deaths. Gliomas are the most common type, comprising 40-90% of central nervous system tumors in different age groups. The incidence of malignant gliomas is approximately 0.5-2 per 100,000 people annually. Standard treatments include surgical resection, radiotherapy, and chemotherapy, yet overall survival remains low, typically 1-3 years post-diagnosis. The study highlights the pressing need for novel treatment strategies, particularly given the infiltrative nature of gliomas and the potential for targeted therapies using neuropeptides.The aim of this study is to assess the efficacy and safety of local targeted therapy with [225Ac]Ac-DOTA-SP in newly diagnosed glioblastoma following standard treatment.It is an interventional study without a control group, initiated by the researcher. Patients included are aged 18-80 with WHO G3-G4 glioma post-first-line treatment, not requiring immediate surgery and meeting specific MRI criteria.Patients will receive a maximum of six cycles of [225Ac]Ac-DOTA-SP, involving pre-treatment assessments, local administration of the agent after ensuring catheter patency, and continuous monitoring. Blood tests and neurological evaluations will be performed regularly.Outcome will be assessed by measuring overall survival (OS) and progression-free survival (PFS). The study anticipates improvements in both OS and PFS when compared to current treatments, contributing to critical insights into targeted alpha therapy's effectiveness in glioblastoma.Treatment with [225Ac]Ac-DOTA-SP previously indicated few significant side effects, primarily transient issues like seizures. Patients will be closely monitored throughout the study to identify any adverse effects promptly.The estimated study duration is three years, with biological material collected for histopathological and genetic analysis during surgical reoperation.Data will be anonymized to protect patient confidentiality, stored securely, and made available only for the scope of the study.Led by Prof. Przemysław Kunert, the research team includes multiple co-investigators from neurosurgery and nuclear medicine departments.

Read the detailed description
  1. Background Brain tumors account for approximately 1.35% of all cancers and are responsible for 2.2% of cancer-related deaths. Gliomas are the most common primary brain tumors and, depending on age group, represent 40%-90% of central nervous system tumors. The incidence of malignant gliomas is estimated at 0.5-2 cases per 100,000 persons per year. These tumors occur more frequently in men, most often in the fifth and sixth decades of life. In Poland, approximately 1,300 patients are diagnosed with gliomas annually, including about 600 with malignant disease.

    Current standard treatment consists of surgery, radiotherapy, and chemotherapy. Nevertheless, prognosis remains poor, with median survival ranging from 1 to 3 years depending on tumor type. Despite treatment, disease progression commonly occurs, and chemotherapy provides only a modest extension of survival. These limitations underscore the need for novel therapeutic strategies.

    Given the infiltrative nature of gliomas, an effective treatment should diffuse throughout the tumor and selectively bind to neoplastic cells. Peptide-based targeted therapy appears particularly promising in this context. Many tumors express membrane receptors at high levels, allowing the use of radioisotope-labeled peptides for diagnosis and therapy. This approach is already applied in selected lymphomas and neuroendocrine tumors.

    In gliomas, particularly WHO grade II-IV, increased expression of neurokinin-1 (NK-1) receptors has been observed. Substance P, the natural ligand for NK-1 receptors, demonstrates rapid diffusion and binding to glioma cells. A derivative of substance P developed at the Institute of Nuclear Medicine, University Hospital Basel, showed that more than 95% of gliomas exhibit elevated NK-1 receptor expression, confirming its potential for targeted therapy.

    Substance P may be labeled with beta-emitting isotopes such as 90Y and 177Lu. However, due to their longer tissue range, these isotopes may pose a risk to adjacent critical brain structures. This limitation prompted interest in alpha emitters such as 213Bi and 225Ac, which have high energy but very short tissue penetration.

    Within the project "Use of Radioisotope-Labeled Substance P in Treating Patients with Brain Tumors" (KB/204/A/201), local treatment with alpha-emitter-labeled substance P was administered in patients with recurrent glioma. Treatment with [213Bi]Bi-DOTA-SP was well tolerated and not associated with clinically significant adverse effects. Median progression-free survival (PFS) was 2.7 months, median overall survival (OS) after recurrence was 10.9 months, and median OS from diagnosis was 23.6 months.

    Because of the short half-life of 213Bi (46 minutes), subsequent studies focused on 225Ac. In a dose-escalation study of [225Ac]Ac-DOTA-SP at activities of 10, 20, and 30 MBq, treatment was also well tolerated. The maximum tolerated dose was determined to be 20 MBq. Median OS from diagnosis was 35 months, median OS from recurrence was 13.2 months, and median PFS from treatment initiation was 2.4 months.

    On the basis of these encouraging findings, the present project proposes radioisotope therapy beginning 2 months after standard treatment in patients with newly diagnosed WHO grade G3-G4 glioma, with the aim of assessing whether [225Ac]Ac-DOTA-SP improves survival and delays disease progression.

  2. Main Objective To evaluate the efficacy of local targeted therapy with the alpha-emitter-labeled neuropeptide [225Ac]Ac-DOTA-SP, administered using the forced diffusion method, in patients with newly diagnosed WHO grade G3-G4 glioma after first-line treatment.

    Secondary Objective To assess the safety of local targeted therapy with [225Ac]Ac-DOTA-SP.

  3. Study Design This is an interventional, investigator-initiated study without a control group. 225Ac will be supplied through a cooperation agreement between the Medical University of Warsaw (WUM) and the Institute for Transuranium Elements in Karlsruhe. The sponsoring institution is the Medical University of Warsaw (WUM).
  4. Study Procedures

    1. Qualification Visit A screening visit will include collection of medical history and review of prior diagnostics and treatment. Relevant medical documentation, including imaging studies (CT and/or MRI), must be provided. The study physician will explain the protocol and answer any questions.
    2. Reoperation and Catheter Placement

      • [68Ga]Ga-PSMA PET/CT will be performed to determine the site for biopsy and catheter placement.
      • Tumor resection with biopsy, or biopsy alone, will be performed.
      • Catheters will be placed, with up to three catheters permitted for lesions larger than 2 cm.
      • This procedure will be carried out in the Departments of Neurosurgery at either the University Clinical Centre (UCK) or the National Oncology Institute (NIO) and will require several days of hospitalization.
    3. Local Treatment with [225Ac]Ac-DOTA-SP

      • Treatment may begin no earlier than 2 months after completion of radiotherapy.
      • Chemotherapy may continue according to the treating oncologist's recommendation.
      • Catheter patency will be assessed approximately one week before the planned treatment.
      • Local administration of 5 MBq of 68Ga in a volume of 1-3 ml will be followed by PET/CT imaging 30 minutes later.
    4. Therapy Administration Patients may receive up to four cycles of [225Ac]Ac-DOTA-SP.
    5. Radiopharmaceutical preparation:

      • Labeling will be performed in the Nuclear Medicine Department at WUM.
      • 68Ga is available from the department's registered 68Ge/68Ga generator.
      • The radiopharmacy team is qualified and experienced in 68Ga labeling.
      • 225Ac will be supplied under the cooperation agreement with the Institute for Transuranium Elements in Karlsruhe.
      • Quality control will be performed to confirm labeling efficiency and radiopharmaceutical purity.
      • If labeling efficiency is below 90%, the product will not be administered.

      Therapeutic administration:

      • Administered activity of [225Ac]Ac-DOTA-SP: 20 MBq
      • Volume: 10%-20% of the resection cavity volume
      • Maximum total amount of substance P: 200 μg combined for 68Ga and 225Ac formulations

      Pre-treatment medication:

      • 250 ml of 15% mannitol
      • 500 ml of 0.9% NaCl
      • 8 mg dexamethasone intravenously
      • These will be administered 20-30 minutes prior to treatment

      Post-administration imaging and monitoring:

      • Immediate brain imaging after administration of [225Ac]Ac-DOTA-SP with 5-10 MBq of [68Ga]Ga-DOTA-SP
      • Saline infusion via pump at 0.5 ml/hour for 2-4 hours
      • Repeat brain imaging 2-4 hours after administration, followed by whole-body scanning
      • Blood and urine testing at 1, 2, 4, and 24 hours after treatment

      SPECT/CT assessment of distribution:

      • SPECT/CT imaging will be performed at 4 hours and 24 hours after administration
      • Imaging will follow a quantitative protocol developed at the Nuclear Medicine Department of UCK, based on phantom studies
      • The protocol includes approximately 30 minutes of SPECT acquisition using multiple energy windows and about 3 minutes of low-dose CT for attenuation correction and anatomical localization Treatment will be conducted at UCK during neurosurgical hospitalization. Based on prior experience, hospitalization has typically lasted 3 days. Previous treatment experience showed good tolerability, with transient facial flushing being the only reported side effect, and seizures occurring in some patients who had a history of seizures before therapy. For this reason, patients will remain hospitalized for 24 hours after therapy in the Department of Neurosurgery (UCK).

      If treatment is poorly tolerated, it will not be continued. Steroid therapy will be initiated if not already in place, and seizures will be managed according to standard anticonvulsant protocols.

      Monitoring Before Each Subsequent Cycle and 2-4 Weeks After Administration

      • Hematology
      • AST, ALT
      • Sodium, potassium
      • Creatinine, urea
      • CRP
      • INR
      • D-dimers
      • Karnofsky Performance Status (KPS)
      • Barthel Index
      • Assessment of adverse events Follow-Up
      • MRI with contrast will be performed every 2 months to assess treatment efficacy and approximately 2 weeks before each administration of [225Ac]Ac-DOTA-SP.
      • Follow-up visits, including telemedicine if needed, will be conducted every 2 months during the first 18 months, or more frequently if clinically indicated.
      • After 18 months, follow-up will occur every 3 months or more often as required.
    6. Discontinuation of Therapy

    Therapy will be discontinued in the event of:

    • serious adverse events
    • concomitant illness preventing further treatment
    • disease progression
    • withdrawal of consent by the patient
    • changes in the patient's condition that, in the investigator's opinion, preclude continued treatment The investigator may also withdraw a patient for safety reasons if unforeseen circumstances arise.
  5. Sample Size The target sample size is 25 patients. To account for possible dropout, up to 35 patients may be enrolled. Participants will be recruited from the neurosurgical departments of UCK and NIO.
  6. Study Endpoints Primary Endpoint

    Progression-free survival (PFS), defined as the time to progression based on:

    • Clinical progression: deterioration in Karnofsky Performance Status, worsening neurological function, or need for initiation/increase of corticosteroids by more than 50%
    • Radiological progression on MRI: local progression within 4 cm of the margin of the primary lesion after resection, appearance of a new lesion, or increase in lesion size by more than 25% between consecutive imaging studies Radiation necrosis will be considered in the differential diagnosis, with MRI perfusion and/or biopsy performed as needed.

    Secondary Endpoints

    • Overall survival (OS) from the date of diagnosis
    • Safety assessment of the treatment
  7. Expected Benefits The study is intended to evaluate the efficacy and safety of [225Ac]Ac-DOTA-SP as an adjunct to standard therapy. It is anticipated that this approach may prolong survival and delay disease progression compared with currently available treatment methods.
  8. Risks and Discomforts Based on current experience, treatment with [225Ac]Ac-DOTA-SP has not been associated with clinically significant adverse effects. The most frequently reported adverse event has been seizures, although these were present before treatment in all affected patients. No clinically significant abnormalities have been observed in laboratory tests.

    At present, there is no conclusive scientific evidence that the local radioactivity used in this treatment increases the risk of secondary malignancy or hereditary defects. However, efficacy as supplementary treatment after standard therapy has not yet been definitively established.

  9. Study Duration The estimated duration of the study is 3 years. Patients who remain alive at the end of the study will continue to be followed until death is reported.
  10. Biological Material During reoperation and catheter placement, tissue will be collected for histopathological and genetic analyses in accordance with standard clinical procedures.
  11. Data Anonymization No directly identifiable patient data will be stored with the medical data used for analysis. All data will be analyzed anonymously, with each patient assigned an individual study number corresponding to the anonymization list.
03

Conditions studied

  • Glioblastoma
  • High-Grade Glioma (WHO III-IV)
  • Glioblastoma (GBM)

Keywords

  • alpha emitter
  • glioblastoma
  • local therapy
  • 225-Ac
  • high-grade glioma
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age 18-80;
  • confirmed diffuse glioma (CNS WHO G3-G4);
  • after standard treatment with or resection, radiotherapy and/or chemotherapy;
  • no sign of progression or radiation necrosis;
  • functional state >70 according to 's performance scale (KPS);
  • ability to give to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • low-grade glioma;
  • progression or recurrence defined as: deterioration of the patient's condition according to the Performance Scale, worsening of neurological function, progressive neurological deficit, need to initiate or increase dose by >50%, progression or recurrence assessed on MRI (RANO criteria);
  • radiation-induced necrosis secondary to radiotherapy; may occur within the first 3 months after radiotherapy (exception: a patient after resection of radiation necrosis - not earlier than 4 weeks post-surgery, after a follow-up MRI);
  • need for emergency surgery (e.g., acute increase in intracranial pressure);
  • significant postoperative complications, e.g., KPS \< 70, wound infection, cerebrospinal fluid leak;
  • leak into the ventricular system >10% during the catheter patency check;
  • open/ventricle-connected resection cavity;
  • catheter obstruction;
  • estimated under 3 months;
  • patients without preserved logical/verbal contact;
  • lack of cooperation from the patient;
  • inability to give informed, voluntary consent to participate in the study;
  • patients enrolled in another medical trial;
  • patients who received any other drug within 1 month prior to the first dose;
  • prior treatment with [225Ac]Ac-DOTA-SP;
  • breastfeeding or pregnant women;
  • severe comorbid organ diseases that, in the Investigator's opinion, significantly increase the procedural risk.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    Experimental : HGG treated with alpha emitter [225Ac]Ac-DOTA-SP (TAT) after standard therapy

    Patients with high-grade gliomas (WHO G3-G4) after standard therapy who are treated with local, targeted therapy with alpha emitter \[225Ac\]Ac-DOTA-SP (TAT)

    Radiation: Radiation: Local, targeted therapy with alpha emitter [225Ac]Ac-DOTA-SP (TAT)

Interventions

  • RadiationRadiation: Local, targeted therapy with alpha emitter [225Ac]Ac-DOTA-SP (TAT)

    Local, targeted therapy with alpha emitter \[225Ac\]Ac-DOTA-SP (TAT) administered to the post-resection cavity or tumour via Rickham reservoir using induced diffusion.

06

What researchers measure

Primary outcomes

  1. 1. Number of patients experiencing clinical progression (as defined below)

    Clinical progression defined by: * reduction in Karnofsky Performance Scale result below 70% OR * new focal neurological deficit or exacerbation of existing deficit OR * necessity to use or increase dexamethasone dose by 50% or more.

    Time frame: From enrollment to 18 months

Secondary outcomes

  1. 2. Number of patients experiencing radiological progression (as defined below)

    Radiological progression assessed on contrast-enhanced cerebral MRI: * any new contrast-enhanced lesion OR * 25% or more increase in contrast-enhancing lesions despite stable or increasing steroid dose OR * significant increase in non-enhancing FLAIR/T2W lesions, not attributable to other non-tumour causes.

    Time frame: From enrollment to 18 months

  2. 3. Number of patients experiencing local radiological progression (as defined below)

    Local radiological progression assessed on contrast-enhanced cerebral MRI: * any new contrast-enhanced lesion within 4 cm from resection cavity OR * 25% or more increase in contrast-enhancing lesions within 4 cm from resection cavity despite stable or increasing steroid dose.

    Time frame: From enrollment to 18 months

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Krolicki L, Kunikowska J, Bruchertseifer F, Kulinski R, Pawlak D, Koziara H, Rola R, Morgenstern A, Merlo A. Locoregional Treatment of Glioblastoma With Targeted alpha Therapy: [ 213 Bi]Bi-DOTA-Substance P Versus [ 225 Ac]Ac-DOTA-Substance P-Analysis of Influence Parameters. Clin Nucl Med. 2023 May 1;48(5):387-392. doi: 10.1097/RLU.0000000000004608. Epub 2023 Mar 1. PubMed 36854309 ↗
  • Krolicki L, Bruchertseifer F, Kunikowska J, Koziara H, Krolicki B, Jakucinski M, Pawlak D, Apostolidis C, Mirzadeh S, Rola R, Merlo A, Morgenstern A. Safety and efficacy of targeted alpha therapy with 213Bi-DOTA-substance P in recurrent glioblastoma. Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):614-622. doi: 10.1007/s00259-018-4225-7. Epub 2018 Nov 29. PubMed 30498897 ↗
  • Krolicki L, Bruchertseifer F, Kunikowska J, Koziara H, Pawlak D, Kulinski R, Rola R, Merlo A, Morgenstern A. Dose escalation study of targeted alpha therapy with [225Ac]Ac-DOTA-substance P in recurrence glioblastoma - safety and efficacy. Eur J Nucl Med Mol Imaging. 2021 Oct;48(11):3595-3605. doi: 10.1007/s00259-021-05350-y. Epub 2021 Apr 15. PubMed 33860346 ↗
  • Cordier D, Forrer F, Kneifel S, Sailer M, Mariani L, Macke H, Muller-Brand J, Merlo A. Neoadjuvant targeting of glioblastoma multiforme with radiolabeled DOTAGA-substance P--results from a phase I study. J Neurooncol. 2010 Oct;100(1):129-36. doi: 10.1007/s11060-010-0153-5. Epub 2010 Mar 10. PubMed 20217458 ↗
  • Cordier D, Forrer F, Bruchertseifer F, Morgenstern A, Apostolidis C, Good S, Muller-Brand J, Macke H, Reubi JC, Merlo A. Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial. Eur J Nucl Med Mol Imaging. 2010 Jul;37(7):1335-44. doi: 10.1007/s00259-010-1385-5. Epub 2010 Feb 16. PubMed 20157707 ↗
  • Sykova E, Nicholson C. Diffusion in brain extracellular space. Physiol Rev. 2008 Oct;88(4):1277-340. doi: 10.1152/physrev.00027.2007. PubMed 18923183 ↗
  • Hilario A, Ramos A, Perez-Nunez A, Salvador E, Millan JM, Lagares A, Sepulveda JM, Gonzalez-Leon P, Hernandez-Lain A, Ricoy JR. The added value of apparent diffusion coefficient to cerebral blood volume in the preoperative grading of diffuse gliomas. AJNR Am J Neuroradiol. 2012 Apr;33(4):701-7. doi: 10.3174/ajnr.A2846. Epub 2011 Dec 29. PubMed 22207304 ↗

Individual participant data

Plan to share: Yes — Study protocol and anonymised clinical, radiological and molecular data regarding individual patients will be made available as supplementary materials to published articles.

Supporting information: Study protocol

Time frame: from study conclusion in Sep 2028

Access criteria: Data access will be provided to any researchers possessing access to published articles as supplementary materials or via e-mail on reasonable request.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Sep 2027, 23 months after the start.

Of 133 non-industry interventional studies with no phase under Glioblastoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 97. This study's planned 23 months is below that.

Counting every sponsor, half of 151 studies reached it within 54 months; a quarter within 36 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2026
First posted
Mar 23, 2026
StartActual
Oct 1, 2025
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2028
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07488754
Responsible party
Sponsor
First posted
Mar 23, 2026
Start date
Oct 1, 2025
Primary completion
Sep 2027 (estimated)
Completion
Sep 2028 (estimated)
Last update
Apr 6, 2026

Study contacts

Przemysław Kunert, Professor MD PhD
Contact
przemyslaw.kunert@wum.edu.pl
+48 22 599 2575 ext. +48
Przemysław Kunert, Professor MD PhD
principal investigator · Medical University of Warsaw
Joanna Kunikowska, Professor MD PhD
study director · Medical University of Warsaw

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion